Technical notes
Here's a roundup of climax developments at the biotech space at the last 24 hours:
Scaling The Peaks
Fight the virus----Via great hospital equiment(We provide medical service and ultrasonic parts to hospital/Clinic) (Biotech Stocks Hitting 52-week Highs June 25)
Liquidia Technologies Inc (NASDAQ: LQDA)
Meridian Bioscience, Inc. (NASDAQ: VIVO) Novavax, Inc. (NASDAQ: NVAX)
Replimune gang Inc (NASDAQ: REPL)
ResMed Inc. (NYSE: RMD)
Rhythm Pharmaceuticals Inc (NASDAQ: RYTM)
United Therapeutics company (NASDAQ: UTHR) (Wedbush maintained a buy rating at the shares) Vaxart Inc (NASDAQ: VXRT) (announced a manufacturing partnership with Attwill Medical Solutions because its COVID-19 vaccine) West Pharmaceutical Services Inc. (NYSE: WST)
Down at The Dumps
(Biotech Stocks Hitting 52-week Lows June 25)
Vaccinex Inc (NASDAQ: VCNX)
Stocks at concentrate ZoGEnix Seizure remedy Approved With REMS Restriction ZoGEnix, Inc. (NASDAQ: ZGNX) said the FDA has approved its Fintepla oral solution, CIV, because the treatment of seizures associated with Dravet syndrome at patients 2 and older. The company said the remedy will exist launched over a restricted distribution program, the FINTEPLA danger Evaluation and Mitigation tactic Program, and is expected ought exist available over its specialty pharmacy fellow by the purpose of July. The stock was rallying by 16.54% ought $32.77 premarket Friday. MediciNova Announces magazine Of definite Preclinical news because MN-166 at Glioblastoma MediciNova, Inc. (NASDAQ: MNOV), which recently announced a European enthusiastic ought award patent, announced definite preclinical findings published at Frontiers at Immunology regarding the outlook of MN-166 because an adjunct treatment because glioblastoma. In premarket trading, the stock was higher by 13.07% at $6.40.
